Edwards Lifesciences (EW) Cvp, Tavr Lippis Buys $45K of Stock
Daniel Lippis, a corporate vice president, purchased shares of Edwards Lifesciences as the stock approaches its 52-week range.
Reviewed by automated data checks against the source filing. How we make and check alerts
Daniel Lippis, CVP, TAVR at Edwards Lifesciences Corporation ($EW), bought 619 shares at an average price of $72.68, worth about $44,988.92, on June 30, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $EW is up 4.8% after 1 week, down 3.9% after 1 month and down 4.3% to date (from the $90.46 close on Jun 30, 2026).
EW
Edwards Lifesciences Corporation
Key Points
- On June 30, 2026, Daniel Lippis bought 619 shares of Edwards Lifesciences (EW) for about $44,988, with the stock priced at $90.46 on the day of the transaction.
- The stock is trading near its 52-week low of $72.30, raising interest among investors as it approaches its next earnings date of October 29, 2026.
- Analysts remain optimistic, with a buy recommendation and a mean price target of $100.96, indicating potential for stock growth.
Get $EW trade alerts by text
We text you when insiders, Congress or big funds trade $EW. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Edwards Lifesciences Corporation alert may contain errors. Disclosures
Lippis Boosts Stake in Edwards Lifesciences
On June 30, 2026, Daniel Lippis, a corporate vice president at Edwards Lifesciences Corporation, bought 619 shares of the company, valued at about $44,988, as reported in his recent transaction. The shares were acquired at an average price of $72.68 per share while the stock was priced at $90.46 on the publication date of this article.
Lippis's purchase reflects a commitment to the company, which specializes in medical devices for treating advanced cardiovascular diseases. With this new buy, Lippis adds to his stake, signaling a positive outlook despite the stock trading near its 52-week low.
Institutional Activity in Edwards Lifesciences
No additional fund activity was reported in relation to Edwards Lifesciences in this filing period. However, Lippis's recent transaction may attract attention from other investors looking to gauge insider confidence.
Stock Is Near Its 52-Week Low
Edwards Lifesciences is currently trading close to its 52-week low of $72.30. This creates an interesting dynamic for investors, particularly as the stock has seen a price range between $72.30 and $96.29 in the past year. The upcoming earnings report, scheduled for October 29, 2026, will also be crucial in assessing how the company is performing against its peers in the medical device industry.
Recent Earnings
Edwards Lifesciences reported revenue of approximately $6.51 billion, showing a growth rate of about 13.6%. The company posted earnings per share of $1.68, along with a net margin of 15.4%. With the next earnings announcement set for October 29, 2026, investors will be keen to see if the company continues on this growth trajectory.
Analysts Set New Price Targets
Several firms recently updated their ratings on Edwards Lifesciences. On October 7, 2026, Barclays initiated coverage with an Overweight rating and a target price of $110. BTIG reiterated its Buy rating with the same $110 target on September 11, 2026. Additionally, Leerink Partners upgraded its rating to Outperform with a target of $101 on July 25, 2026. These upgrades suggest a favorable outlook from analysts who see growth potential in the company.
What Edwards Lifesciences Corporation Does
Edwards Lifesciences Corporation focuses on delivering products and technologies for advanced cardiovascular care. Its innovations include solutions for heart valve replacements and repairs. As the company navigates market challenges, insider transactions like Lippis's buy may signal management's confidence in the firm's direction and product offerings.
What's Ahead for Edwards Lifesciences Corporation
Investors should watch for the upcoming earnings report on October 29, 2026, which will offer insights into the company's performance. Remember, Lippis's purchase reflects past activity and may not necessarily indicate current positions or future trades.
Related Filing Alerts
Source: Daniel Lippis's Form 4 filing on $EW (Jun 30, 2026). Find the original filing: EW Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts